+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Failure of thromboxane synthetase inhibition to protect the postinfarcted heart against the induction of ventricular tachycardia and ventricular fibrillation in a conscious canine model of sudden coronary death



Failure of thromboxane synthetase inhibition to protect the postinfarcted heart against the induction of ventricular tachycardia and ventricular fibrillation in a conscious canine model of sudden coronary death



Pharmacology 37(3): 171-186



The role of thromboxane as a contributor to the genesis of ventricular tachycardia and fibrillation was examined in conscious dogs which had been subjected to myocardial infarction. CGS 12970, a thromboxane synthetase inhibitor was administered in a dose of 10 mg/kg (i.v.) every 12 h. Ex vivo thrombin-activated thromboxane synthesis, as determined by assay for thromboxane B2, was reduced to 15% of baseline 2 h after administration of CGS 12970. Drug administration was found to inhibit ex vivo platelet aggregation significantly in response to arachidonic acid, while aggregation to ADP and collagen was unaffected. CGS 12970 did not protect against the induction of ventricular tachycardia by programmed electrical stimulation of the postinfarcted heart. During provocative electrical stimulation, 9 of 11 (82%) animals continued to respond in the post-treatment period with the development of VT. Pretreatment with CGS 12970 failed to prevent the spontaneous development of ventricular fibrillation which occurred in 7 of 10 (70%) animals when a secondary ischemic event was superimposed in the region of the noninfarct-related circumflex coronary artery. The results suggest that the thromboxane synthetase inhibitor, CGS 12970, when administered in the subacute phase of recovery from myocardial infarction, does not protect against the induction of ventricular tachycardia by programmed electrical stimulation or the spontaneous development of ventricular fibrillation in the postinfarcted canine heart. The findings suggest that thromboxane may not serve a critical role in the genesis of ventricular tachyarrhythmias and ventricular fibrillation in the postinfarcted canine heart.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 005444434

Download citation: RISBibTeXText

PMID: 3227051


Related references

Failure of Thromboxane Synthetase Inhibition to Protect the Postinfarcted Heart against the Induction of Ventricular Tachycardia and Ventricular Fibrillation in a Conscious Canine Model of Sudden Coronary Death. Pharmacology 37(3): 171-186, 1988

Effect of flecainide acetate on ventricular tachycardia induction and ventricular fibrillation prevention in a conscious canine model of sudden death. Journal of the American College of Cardiology 7(2 SUPPL A): 84A, 1986

Effect of flecainide acetate on prevention of electrical induction of ventricular tachycardia and occurrence of ischemic ventricular fibrillation during the early postmyocardial infarction period evaluation in a conscious canine model of sudden death. Journal of the American College of Cardiology 9(2): 359-365, 1987

Prostacyclin on ventricular fibrillation in a conscious canine model of sudden coronary death. Naunyn-Schmiedeberg's Archives of Pharmacology 321(SUPPL): R54, 1982

The KATP channel antagonist 5-hydroxydecanoate fails to protect against ventricular fibrillation in a conscious canine model of sudden cardiac death. FASEB Journal 9(3): A605, 1995

Prevention of ventricular fibrillation by bretylium in a conscious canine model of sudden coronary death. American Heart Journal 105(5): 711-717, 1983

Prevention of ventricular fibrillation by bretylium in a conscious canine model of sudden coronary death. American Heart Association Monograph (82): IV-125, 1981

Prevention of ventricular fibrillation by dextro sotalol in a conscious canine model of sudden coronary death. American Heart Journal 109(5 PART 1): 949-958, 1985

Prevention of ventricular fibrillation by dextrorotatory sotalol in a conscious canine model of sudden coronary death. American Heart Journal 109(5 Pt 1): 949-958, 1985

Ventricular fibrillation resulting from ischemia at a distant site in conscious canine model of sudden coronary death. American Heart Association Monograph (82): IV-218, 1981

Ventricular fibrillation in a conscious canine model of sudden coronary death prevention by chronic amiodarone therapy. American Heart Association Monograph: I-132, 1982

Protection from ventricular fibrillation by um 272 2 hydroxy n n dimethyl n 1 methylethyl 3 1 naphthalenyloxy 1 propanaminium iodide in a conscious canine model of sudden coronary death. Federation Proceedings 41(5): ABSTRACT 8433, 1982

Ventricular fibrillation resulting from ischemia at a site remote from previous myocardial infarction. A conscious canine model of sudden coronary death. American Journal of Cardiology 50(6): 1414-1423, 1982

Induction of ventricular fibrillation during antiarrhythmic drug treatment predicts sudden death in patients with sustained monomorphic ventricular tachycardia or ventricular fibrillation after myocardial infarction. Circulation 90(4 PART 2): I455, 1994

Celiprolol does not protect against ventricular tachycardia or sudden death in the conscious canine: a comparison with pindolol in assessing the role of intrinsic sympathomimetic activity. Journal of Pharmacology and Experimental Therapeutics 251(2): 571-577, 1989